[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kjelgaard‐Petersen et al., 2018 - Google Patents

Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis

Kjelgaard‐Petersen et al., 2018

View HTML
Document ID
15347537039515221267
Author
Kjelgaard‐Petersen C
Platt A
Braddock M
Jenkins M
Musa K
Graham E
Gantzel T
Slynn G
Weinblatt M
Karsdal M
Thudium C
Bay‐Jensen A
Publication year
Publication venue
Arthritis & Rheumatology

External Links

Snippet

Objective Rheumatoid arthritis (RA) is a chronic and degenerative autoimmune joint disease that leads to disability, reduced quality of life, and increased mortality. Although several synthetic and biologic disease‐modifying antirheumatic drugs are available, there is still a …
Continue reading at acrjournals.onlinelibrary.wiley.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis

Similar Documents

Publication Publication Date Title
Kjelgaard‐Petersen et al. Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis
Reker et al. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo
Weinblatt et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve‐week, randomized, placebo‐controlled trial
Cole et al. Fibrin accumulation secondary to loss of plasmin‐mediated fibrinolysis drives inflammatory osteoporosis in mice
Xing et al. Targeted disruption of leucine‐rich repeat kinase 1 but not leucine‐rich repeat kinase 2 in mice causes severe osteopetrosis
Disatian et al. Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease
Cui et al. Endothelial PDGF-BB/PDGFR-β signaling promotes osteoarthritis by enhancing angiogenesis-dependent abnormal subchondral bone formation
Ota et al. Role of chondrocytes in the development of rheumatoid arthritis via transmembrane protein 147–mediated NF‐κB activation
Rucci et al. Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets
Wang et al. Activation Of B-Catenin Signalling Leads To Temporomandibular Joint Defects
Ramaswamy et al. Gsα controls cortical bone quality by regulating osteoclast differentiation via cAMP/PKA and β-catenin pathways
Hannon et al. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study
Han et al. Periostin interaction with discoidin domain receptor-1 (DDR1) promotes cartilage degeneration
Nozawa et al. Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass
Chen et al. TIMP Loss Activates Metalloproteinase‐TNFα‐DKK1 Axis To Compromise Wnt Signaling and Bone Mass
Kjelgaard-Petersen et al. Tofacitinib and TPCA-1 exert chondroprotective effects on extracellular matrix turnover in bovine articular cartilage ex vivo
Yang et al. Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss
Greisen et al. The programmed death-1 pathway counter-regulates inflammation-induced osteoclast activity in clinical and experimental settings
Wang et al. Hedgehog signaling orchestrates cartilage-to-bone transition independently of Smoothened
Daniels et al. Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack.
Zhang et al. A novel signaling pathway: fibroblast nicotinic receptor α1 binds urokinase and promotes renal fibrosis
US9526782B2 (en) Pharmaceutical compositions comprising inhibitors of zinc-ZIP8-MTF1 as active ingredients for preventing or treating a joint disease
Jo et al. A novel role for bone-derived cells in ankylosing spondylitis: focus on IL-23
US9381245B2 (en) Methods for inhibiting osteolysis
Maleitzke et al. Inactivation of the gene encoding procalcitonin prevents antibody-mediated arthritis